

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

Rh41

RRID:CVCL_2176

Type: Cell Line

Proper Citation

RRID:CVCL_2176

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2176

Proper Citation: RRID:CVCL_2176

Description: Cell line Rh41 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Alveolar rhabdomyosarcoma

Defining Citation: [PMID:11051265](#), [PMID:17471488](#), [PMID:19235922](#), [PMID:20922763](#), [PMID:22142829](#), [PMID:22460905](#), [PMID:23665679](#), [PMID:23882450](#), [PMID:26351324](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31448612](#), [PMID:31978347](#), [PMID:32758582](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Rh41

Synonyms: RH41, RH-41, Rh-41, SJ-Rh41

Cross References: CLO:CLO_0037075, EFO:EFO_0022719, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473491, BioSample:SAMN10988473, cancercellines:CVCL_2176, Cell_Model_Passport:SIDM00426, Cosmic:1620039, Cosmic:1718364, Cosmic:1995621, Cosmic:2820089, Cosmic-CLP:1240210, DepMap:ACH-000100, DSMZ:ACC-592, DSMZCellDive:ACC-592, EGA:EGAS00001000978, GDSC:1240210, GEO:GSM219748,

GEO:GSM887538, GEO:GSM888621, GEO:GSM1670378, GEO:GSM1676313, GEO:GSM1701647, LiGeA:CCLE_645, LINCS_LDP:LCL-1415, PharmacDB:RH41_1313_2019, PRIDE:PXD007755, PRIDE:PXD030304, Progenetix:CVCL_2176, Wikidata:Q54950346

ID: CVCL_2176

Record Creation Time: 20220427T221459+0000

Record Last Update: 20260829T235734+0000

Ratings and Alerts

No rating or validation information has been found for Rh41.

No alerts have been found for Rh41.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Kim A, et al. (2026) NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition. Molecular cancer therapeutics.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. Molecular cancer therapeutics, 25(3), 493.

Ying W, et al. (2026) Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma. JCI insight, 11(3).

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer immunology research, 13(10), 1591.

Paras KI, et al. (2025) PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma. Cancer research, 85(23), 4718.

Danielli SG, et al. (2024) Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics, 23(6), 864.

Long AW, et al. (2024) Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. Journal of hematology &

oncology, 17(1), 20.

McKay-Corkum GB, et al. (2023) Inhibition of NAD⁺-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4479.

Danielli SG, et al. (2023) Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. *Science advances*, 9(6), eade9238.

Nakazawa K, et al. (2023) Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. *Cancer research communications*, 3(10), 2030.

Milton CI, et al. (2022) FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. *Molecular oncology*, 16(6), 1272.

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. *Molecular cancer therapeutics*, 21(4), 635.

Haydn T, et al. (2020) Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells. *International journal of cancer*, 146(12), 3435.

Brien GL, et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. *eLife*, 7.